40 results about "Pharmaceutical Databases" patented technology

A method and system to track medication containers as they are shipped and as the medication in the containers is dispensed and to verify that medication in containers is properly identified by using a unique container code associated with each medication container, to enter information about the medication in a medication database, and to later retrieve the information stored in the medication database about the medication allowing a determination to be made that the medication has been distributed in error or fraudulently, for example that the medication has not been properly registered in the database.

Provided are a system and method for presenting information related to a drug dilution. A computer memory stores a drug database with a plurality of drug entries, each of which includes an identification and concentration of a drug stored in an originating container. A reader is operable to read a barcode associated with the drug identifier of the originating drug container and the concentration and / or dose and volume of the drug in the container. A user selects or enters a desired drug preparation that may include one or more preparations of the originating drug requested for administration to a patient. A computer processor interprets the concentrate signal, identifies the concentration of the originating drug based on content included in the drug database, and determines a recipe to be presented to the user for preparing the drug including any required dilutions.

The invention provides a drug interaction relationship extraction method and system based on external knowledge, and the method comprises the following steps: carrying out the analysis and processingof the content of a drug database, extracting and generating interacted drug pairs, storing all drug description information, and forming a drug interaction data set with the drug description information; constructing a drug description system information training model, and performing training through the drug interaction data set to obtain and store an optimal model; combining the optimal modelwith a BiLSTM-Att-CapsNet model, so that an EK-BiLSTM-Att-CapsNet model can be obtained, meanwhile, drug entities of the drug interaction data set are recognized, corresponding drug description information is found in a drug database and stored, and finally, the combined model is trained to obtain a final relationship extraction model. According to the method, the problem of large difference of extraction results of different relationship categories can be relieved, and the extraction effect is improved.

The invention provides a traditional drug toxicity evaluation method and a system thereof. A qualitative forecasting method comprises the following steps of: (I) determining the chemical components of a to-be-evaluated traditional drug; and (II) evaluating the toxicity according to the chemical components of the traditional drug. An evaluation forecasting system at least comprises an input module, an output module, a storage module, a traditional drug database, a toxic compound library, a compound toxicity forecasting module and a data processing module. The system and method can accurately forecast the toxicity risk of the drug in research in time for development of a traditional drug, and greatly save money and time; and the system and method provided by the invention also can be used for improving the formula of a traditional drug. The framework of the system provided by the invention has good flexibility and expandability, and can be conveniently used for forecasting other biological activities of the traditional drug.

The present disclosure relates generally to discovery of novel compounds involved in the treatment and prevention of suicidality by bioinformatics drug repurposing using novel genes expression biomarkers involved in suicidality. Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for suicidality. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in preventing and treating suicidality. These methods include computer-assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. Detailed herein are methods using a universal approach, in everybody, as well as personalized approaches by gender, and by diagnosis. The discovery describes compounds for use in everybody (universal), as well as personalized by gender (males, females), diagnosis (bipolar, depression), gender and diagnosis combined (male bipolar, male depression), male PTSD, male SZ / SZA), and subtypes of suicidality (high anxiety, low mood, combined (affective), and high psychosis (non-affective). Also disclosed are methods for identifying which subjects should be receiving which treatment, using genes expression biomarkers for patient stratification and measuring response to treatment. The disclosure also relates to algorithms, universal and personalized by gender and diagnosis. The algorithms combine biomarkers as well as clinical measures for suicidality and for mental state, in order to identify subjects who are at risk of committing suicide, as well as to track responses to treatments. The disclosure further relates to determining subtypes of suicidality. Such subtypes may delineate groups of individuals that are more homogenous in terms of biology, behavior, and response to treatment.